Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19 After Infection and Vaccination

NCT04746092 is registered in ClinicalTrials.gov with Tel-Aviv Sourasky Medical Center as lead sponsor.

NCT NCT04746092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04746092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19 After Infection and Vaccination
Lead sponsor
Tel-Aviv Sourasky Medical Center
Phase
Observational
Overall status
Unknown status
Start date
January 6, 2021
Completion date
May 24, 2022
Enrollment
630 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cll, lymphoma, multiple myeloma